tipifarnib has been researched along with celecoxib in 3 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 5,273 | 843 | 2,428 |
| Protein | Taxonomy | tipifarnib (IC50) | celecoxib (IC50) |
|---|---|---|---|
| Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
| Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
| Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
| Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
| Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
| Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
| Procathepsin L | Homo sapiens (human) | 0.56 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
| Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
| Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
| Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
| Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
| Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
| Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
3 other study(ies) available for tipifarnib and celecoxib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |